The speciality healthcare company SteinCares and biopharma Shilpa Biologicals have announced a strategic licensing agreement to commercialise a biosimilar across Latin America.
Under the new agreement, SteinCares will have exclusive rights to register, commercialise and distribute the biosimilar throughout the region.
At the same time, Shilpa will complete product development and provide long-term commercial manufacturing from its facility in Dharwad, India.
"We are excited to partner with Shilpa Biologicals to bring this biosimilar to Latin America," said Mitchell Waserstein, CEO of SteinCares.
This agreement reinforces our leadership in biosimilars and our role as a strategic partner for global biopharmaceutical companies seeking to enter Latin America's complex healthcare markets.
He added that the partnership would create "scalable healthcare opportunities and [expand] access to innovative, cost-effective treatments across the region."
In a statement, Shilpa said that the new partnership will enhance SteinCares' history of successfully introducing biosimilars in the region and strengthen its speciality care portfolio, "empowering patients with safe and cost-effective treatments throughout Latin America."
"SteinCares is a trusted partner in Latin America with proven expertise in the registration and commercialisation of speciality therapies," said Dr Sridevi Khambhampaty, CEO of Shilpa Biologicals.
"Through this licensing agreement, we are entering Latin America and aim to broaden patient access to safe treatments across the region."
"We believe this collaboration will create meaningful value for patients, healthcare systems and our organisations as we expand our biosimilars footprint in Latin America."
This collaboration reinforces our commitment to scalable, long-term global licensing partnerships and creates a strong platform for future collaborations across key international markets and our growing biosimilars portfolio.